Skip to main content

Table 1 Characteristics of included studies

From: Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma

Author, year
Strategy
Age
Median
F/M (n/N) TFD (Y)
Median
Cytogenetic
F/U/M
Drug dose
mg/m2
Prior therapy median Prior therapy Regimen ORR PFS (m) OS (m) Study design
Bort Lena   
Carfilzomib combinations for R/RMM
 Berdeja 2015 [5] 66 27/17 20/27/36/45 5 (1–10) CP 0.67 7.7 Phase I/II
 Shan 2015 [6] 64 12/20 5.9 10/−/− 20/27/36/45/56 6 (2–12) 31 32 CPD 0.50 7.2 20.6 Phase I
 Berenson 2014(1) [7] 67 13/25 4.2 20/27/36/45 0.43 9.9 15.8 Phase I/II
 Niesvizky 2013 [8] 61.5 18/22 3.3 25/11/4 15/20/27 2 (1–3) 30 28 CRD 0.62 10.2 Phase Ib
 Papadopoulos 2015 [9] 59.5 5/17 3.6 14/7/1 20/36/45/56/70 4(2–9) 21 CD 0.55 Phase I
 Stewart 2015 [10] 64.0 181/215 3.0 48/147/201 20/27 2(1–3) 261 79 CRD 0.87 26.3 phase I/II
 Wang 2013 [11] 61.5 36/48 3.1 57/22/5 20/27 2 (1–5) 65 59 CRD 0.69 11.8 Phase II
 Berenson 2014 (2) [12] 63 20/45/56/70/88 1(1–2) CD 0.67 Phase I/II
 Dimopoulos 2015 [13] 20/56 CD 0.77 Phase III
 Kaufman 2014 [14] 64.5 20/36/45 CP 0.50 14.3 Phase I
 Vesole 2015 [15] 61 7/10 4 3/12/2 15/20/27 4 (1–9) 17 16 QUAD 0.53 12 Phase I
Panobinostat combinations for R/RMM
 Offidani 2012 [16] 73 5/7 15 8 5 PMT 0.41 14.3 Phase II
  65 10/9 10 16 9 PMT 0.37 14.3 Phase II
 Richardson 2013 [17] 61 26/29 4.6 2/35/18   4 (2–11) 55 54 PBD 0.34 5.4 Phase II
 San-Miguel 2013 [18] 62 19/43 10/20/25/30 2 (1–10) 39 28 PBD 0.52 Phase Ib
 Kaufman 2014 [14] 64.5 15-20 CP 0.50 14.3 Phase I
 Berenson 2014 [19] 65 15/25 20 4(1–16) PM 0.07 Phase I/II
 San-Miguel 2014 [20] 63 185/202 20 169 72 PBD 0.61 11 · 99 33 · 6 Phase III
 Berdeja 2015 [5] 66 27/17 20/30 5 (1–10) CP 0.67 7.7   Phase I/II
Elotuzumab combinations for R/RMM
 Jakubowiak 2012 [21] 63 20/18 3.5 2.5/4.0/10/20 2(1–3) 11 13 EB 0.48 9.46 Phase I
 lonial 2012 [22] 60 5.2 26/3/0 2.5/10/20 3(1–10) 20 6 ERD 0.82   Phase I
 lonial 2015 [23] 67 10 2(1–4) 219 16 ERD 0.79 19.4 Phase III
 Richardson 2015 [24] 60.6 17/19 4.76 32/1/3 10 22 ERD 0.92 32 · 49 Phase Ib-II
  63.3 13/24 4.96 27/3/7 20 22 ERD 0.76 25 · 00 Phase Ib–II
  1. Abbreviations: F female; M male; TFD time from diagnosis; F/U/M favor/unfavor/miss; CFZ carfilzomib; Bor bortezomib; Lena lenalidomide; CPD carfilzomib, pomalidomide, and dexamethasone; Replacement of bortezomib with carfilzomib from bortezomib combination therapy, CD carfilzomib, dexamethasone; CRD Carfilzomib, lenalidomide, and dexamethasone; CP carfilzomib, panobinostat; CCD carfilzomib, cyclophosphamide, and dexamethasone; QUAD carfilzomib, lenalidomide, vorinostat, and dexamethasone; PMT panobinostat melphalan prednisone; PBD panobinostat, bortezomib, and dexamethasone; EB elotuzumab bortezomib, ERD elotuzumab, lenalidomide, and dexamethasone